Boston, MA, United States of America

Sean Anthony McCarthy

This inventor holds 13 USPTO granted patents and 7 published patent applications, primarily in Neuroscience Proteins. Top assignees: Millennium Pharmaceuticals Limited, Millennium Biotherapeutics, Inc., Millenium Pharmaceuticals, Inc.. Active years: 1999-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sean Anthony McCarthy. Retrieved from https://idiyas.com/inventor/sean-anthony-mccarthy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 53.8

Average Co-Inventor Count = 1.6

ph-index = 6

Forward Citations = 133(Granted Patents)


Location History:

  • Boston, MA (US) (1999 - 2006)
  • San Diego, CA (US) (2006 - 2012)

Company Filing History:


Years Active: 1999-2012

Loading Chart...
Areas of Expertise:
Dickkopf-1 Proteins
Nucleic Acid Molecules
Neural Adhesion Proteins
Delta3 Protein
Polypeptides
Gene Encoding
Signal Sequences
Lipase-like Protein
Antibodies
Human Proteins
Secreted Proteins
Nucleic Acids
13 patents (USPTO):Explore Patents

Title: Sean Anthony McCarthy: Innovator in Biotherapeutics

Introduction

Sean Anthony McCarthy is a prominent inventor based in Boston, MA, known for his significant contributions to the field of biotherapeutics. With a total of 13 patents to his name, McCarthy has made remarkable advancements in the understanding and application of various proteins and nucleic acid molecules.

Latest Patents

Among his latest patents, McCarthy has developed innovative technologies related to human Dickkopf-related proteins and nucleic acid molecules. This invention includes novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules. It provides isolated, full-length Dkk and Dkk-related proteins, as well as isolated fusion proteins, antigenic peptides, and antibodies. Furthermore, the invention encompasses Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors, host cells, and non-human transgenic animals with introduced or disrupted Dkk genes. Diagnostic, screening, and therapeutic methods utilizing these compositions are also included.

Another significant patent involves Delta3 (tango24) protein and nucleic acid molecules. This invention presents novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129, and A259 polypeptides, proteins, and nucleic acid molecules. It also provides isolated full-length proteins, fusion proteins, antigenic peptides, and antibodies related to these innovations. Similar to his previous work, this patent includes nucleic acid molecules, recombinant expression vectors, host cells, and non-human transgenic animals with introduced or disrupted genes. Diagnostic, screening, and therapeutic methods utilizing these compositions are also provided.

Career Highlights

Throughout his career, McCarthy has worked with notable companies such as Millennium Pharmaceuticals Limited and Millennium Biotherapeutics, Inc. His work in these organizations has contributed to the advancement of biotherapeutic solutions and innovative medical treatments.

Collaborations

Some of McCarthy's notable coworkers include David P. Gearing and Douglas Adam Levinson. Their collaborative efforts have further enhanced the research and development of biotherapeutic innovations.

Conclusion

Sean Anthony McCarthy is a distinguished inventor whose work in biotherapeutics has led to significant advancements in the field. His numerous patents reflect his dedication to innovation and the development of therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…